ONWARD Medical Reports First Half 2026 Results with Strong Product Revenue Growth and Continued Progress across ARC Therapy Pipeline
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD — US ADR: ONWRY), the leading neurotechnology company pioneering the…